Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (308)	3/26/1999 12:42:00 PM
From: Thomas M.	Read Replies (1) \| Respond to of 3158

Certainly a market correction would squeeze the hot air out of SEPR. Tom

To: Mike McFarland who wrote (308)	3/26/1999 1:17:00 PM
From: John Metcalf	Respond to of 3158

Sepracor too big to be taken out? Actually, it might be too small. Most of the mergers have been quite large, as pharmaceutical companies look for sufficient mass to support multinational operations and a major R&D budget. Glaxo and Wellcome, Pharmacia and Upjohn, Zeneca and Astra AB, Ciba-Giegy-Sandoz (Novartis). Corange, Syntex, Boehringer Mannheim. AHP has looked at combinations with Smithkline and Monsanto, which seems to be perpetually on the market. There have been more big takeouts than small. GENIZ and AGPH come to mind amongst the small. More to the point with Sepracor, is whether a big pharma would decrease value by buying SEPR and competing with the drug originator, vs. SEPR collaborating with the originator.